Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody against the protein programmed cell death-ligand 1 (PD-L1) and used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy. Atezolizumab binds to PD-L1, thus preventing its interaction with PD-1 and B7-1. The block of PD-L1 and PD-1 interaction removes inhibition of immune responses such as the anti-tumor immune response but not antibody dependent cellular cytotoxicity.
Atezolizumab Biosimilar Antibody
$205.00 – $2,500.00
Atezolizumab is a humanized immunoglobulin (Ig) G1-kappa monoclonal antibody against human programmed cell death-ligand 1 (PD-L1) protein.
Host/Isotype: Human/IgG1
Class: Monoclonal
Immunogen: Human PD-L1 protein
Production platform: CHO cells
Purification: Affinity chromatography
Storage buffer: PBS, pH 7.2
Storage condition: –20°C
For Research Use Only. Not for use in clinical diagnostics or therapeutics.
Additional information
Antibody Production Scale | 50 ug, 250 ug, 1 mg |
---|---|
Conjugate | None, FITC, HRP, ADC (custom drug) |
You must be logged in to post a review.
Reviews
There are no reviews yet.